Chimeric engulfment receptor (CER) T-cell therapy (CER-1236), to treat acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back (relapsed) or not gotten better with treatment (refractory)

To find out:

CER stands for chimeric engulfment receptors and T stands for T cells, a type of immune cell. This treatment helps your own immune system find and destroy cancer cells.
CER-1236 is a type of CER T-cell therapy that targets the TIM-4 ligand. 
Cyclophosphamide and fludarabine are chemotherapy (chemo) drugs that block the growth of cancer cells. 

To make CER T cells, T cells are collected from you by apheresis. Apheresis is a process to collect cells from the bloodstream using a needle similar to when you donate blood. The T cells are genetically modified to grow synthetic receptors called CERs. CERs help T cells find the cancer cells. The CER T cells are grown in a lab until there are millions of them. Then, they’re given back to you to find and destroy the cancer cells.
 
Before the CER-1236  infusion, you’ll get chemotherapy (chemo) with 2 standard drugs:

Then, CER-1236 is given to you through an IV infusion. The dose of cells you’ll get depends on when you start the trial and how safe it has been.

The clinical trial doctors will watch you closely over 2 years. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 15 years.

The Food and Drug Administration (FDA) has not yet approved CER-1236.